HRP20220609T1 - Novi braf inhibitori i njihovo korištenje za tretiranje kožnih reakcija - Google Patents
Novi braf inhibitori i njihovo korištenje za tretiranje kožnih reakcija Download PDFInfo
- Publication number
- HRP20220609T1 HRP20220609T1 HRP20220609TT HRP20220609T HRP20220609T1 HR P20220609 T1 HRP20220609 T1 HR P20220609T1 HR P20220609T T HRP20220609T T HR P20220609TT HR P20220609 T HRP20220609 T HR P20220609T HR P20220609 T1 HRP20220609 T1 HR P20220609T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- compound
- use according
- phenyl
- formula
- Prior art date
Links
- 238000006243 chemical reaction Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- -1 3-chloro-4-fluorophenyl Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 6
- 239000012828 PI3K inhibitor Substances 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229940121647 egfr inhibitor Drugs 0.000 claims 3
- 229960003445 idelalisib Drugs 0.000 claims 3
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 claims 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 2
- 229940124647 MEK inhibitor Drugs 0.000 claims 2
- 229950003628 buparlisib Drugs 0.000 claims 2
- 229960002271 cobimetinib Drugs 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 229950006418 dactolisib Drugs 0.000 claims 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007933 dermal patch Substances 0.000 claims 2
- 201000005884 exanthem Diseases 0.000 claims 2
- 239000006260 foam Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 230000003779 hair growth Effects 0.000 claims 2
- 239000000017 hydrogel Substances 0.000 claims 2
- 239000006210 lotion Substances 0.000 claims 2
- 206010037844 rash Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 238000007910 systemic administration Methods 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical group C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 claims 1
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 claims 1
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 claims 1
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 claims 1
- 206010067484 Adverse reaction Diseases 0.000 claims 1
- 206010019044 Hair growth abnormal Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 claims 1
- 206010034016 Paronychia Diseases 0.000 claims 1
- 241000029132 Paronychia Species 0.000 claims 1
- 206010037649 Pyogenic granuloma Diseases 0.000 claims 1
- 206010037888 Rash pustular Diseases 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 206010040914 Skin reaction Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 230000006838 adverse reaction Effects 0.000 claims 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950004949 duvelisib Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 210000000720 eyelash Anatomy 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 229960003278 osimertinib Drugs 0.000 claims 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 231100000289 photo-effect Toxicity 0.000 claims 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 210000004761 scalp Anatomy 0.000 claims 1
- 229950010746 selumetinib Drugs 0.000 claims 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 230000035483 skin reaction Effects 0.000 claims 1
- 231100000430 skin reaction Toxicity 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Claims (24)
1. Spoj formule (I):
[image]
pri čemu je R odabran iz skupine koja se sastoji od 3-kloro-4-fluorofenila, 2-fluoro-4-jodofenila, 4-kloro-3-(trifluorometil)fenila, 3-(1,1-dimetiletil)-1 - metil-1H-pirazol-5-il, 3-(trifluorometoksi)fenila, ili farmaceutski prihvatljive soli ili otopine istog.
2. Spoj formule I iz patentnog zahtjeva 1, pri čemu je R 3-(trifluorometoksi) fenil.
3. Spoj formule I iz patentnog zahtjeva 1, za korištenje kod inhibicije aktivnosti BRaf-a.
4. Spoj formule I iz patentnog zahtjeva 1, pri čemu spoj ima faktor iritacije kože (PIF) manji od 5.
5. Spoj formule I iz patentnog zahtjeva 1, pri čemu spoj ima srednji fotoefekt (MPE) manji od 0,15.
6. Farmaceutski sastav, koji obuhvaća:
spoj formule (I):
[image]
pri čemu je R odabran iz skupine koja se sastoji od 3-kloro-4-fluorofenila, 2-fluoro-4-jodofenila, 4-kloro-3-(trifluorometil)fenila, 3-(1,1-dimetiletil)-1 - metil-1H-pirazol-5-ila, 3-(trifluorometoksi)fenila, ili farmaceutski prihvatljive soli ili otopine istog;
i farmaceutski prihvatljivog nosača ili pomoćne tvari.
7. Farmaceutski sastav prema patentnom zahtjevu 6, pri čemu je R 3-(trifluorometoksi) fenil.
8. Farmaceutski sastav prema patentnom zahtjevu 6, pri čemu je sastav formuliran za sustavnu primjenu.
9. Farmaceutski sastav prema patentnom zahtjevu 6, pri čemu je sastav formuliran za topikalnu primjenu.
10. Farmaceutski sastav prema patentnom zahtjevu 6, pri čemu se sastav daje oralno u obliku tablete, kapsule, tekućine, otopine ili praška.
11. Farmaceutski sastav prema patentnom zahtjevu 6, pri čemu je sastav u obliku gela, hidrogela, pomade, kreme, pjene, spreja, losiona, tekućine ili kožnog flastera.
12. Farmaceutski sastav prema patentnom zahtjevu 6, pri čemu je spoj prisutan u koncentraciji od 1% m/m do 5% m/m ukupne mase sastava.
13. Farmaceutski sastav prema patentnom zahtjevu 6, pri čemu je spoj prisutan u koncentraciji od 5% m/m do 10% m/m ukupne mase sastava.
14. Farmaceutski sastav prema patentnom zahtjevu 6, obuhvaćajući terapeutski učinkovitu količinu spoja formule (I) za korištenje u liječenju i/ili ublažavanju kožne nuspojave na EGFR inhibitore, PI3K inhibitore, MEK inhibitore ili njihove kombinacije kod potrebitog subjekta, i
pri čemu je kožna nuspojava odabrana od ankeiformnog osipa, papulopustuloznog osipa, abnormalnog rasta kose na vlasištu, abnormalnog rasta dlaka na licu, abnormalnog rasta kose, abnormalnog rasta trepavica, paronihije sa ili bez piogeničnih granuloma i teleangiektazije.
15. Farmaceutski sastav za korištenje prema patentnom zahtjevu 14, pri čemu je R 3-(trifluorometoksi)-fenil.
16. Farmaceutski sastav za korištenje prema patentnom zahtjevu 14, pri čemu je kožna nuspojava akneiformni osip.
17. Farmaceutski sastav za korištenje prema patentnom zahtjevu 14, pri čemu se subjekt liječi s EGFR inhibitorom, PI3K inhibitorom, MEK inhibitorom ili njihovom kombinacijom, prije davanja farmaceutskog sastava.
18. Farmaceutski sastav za korištenje prema patentnom zahtjevu 14, pri čemu je EGFR inhibitor odabran od: gefitiniba, erlotiniba, Lapatiniba, cetuksimaba, panitumumaba, vandetaniba, necitumumaba, osimertiniba i njihovih kombinacija.
19. Farmaceutski sastav za korištenje prema patentnom zahtjevu 14, pri čemu je PI3K inhibitor odabran od GDC-0980 (Apitolisib), GDC-0941 (Pictilisib), BAY 80-6946 (Copanlisib), BKM120 (Buparlisib), NVP-BEZ235 (Dactolisib), IPI 145 (Duvelisib), Idelalisib (GS-1101 or CAL-101), wortmannin i LY294002 i njihovih kombinacija.
20. Farmaceutski sastav za korištenje prema patentnom zahtjevu 14, pri čemu je MEK inhibitor odabran od Trametiniba (GSK1120212), Cobimetiniba (XL518), Binimetiniba (MEK162), Selumetiniba, PD-325901, CI-1040, PD035901, UO126, TAK-733 i njihovih kombinacija.
21. Farmaceutski sastav za korištenje prema patentnom zahtjevu 14, za topikalnu primjenu.
22. Farmaceutski sastav za korištenje prema patentnom zahtjevu 14, u obliku gela, hidrogela, pomade, kreme, spreja, kožnog flastera, pjene, losiona ili tekućine.
23. Farmaceutski sastav za korištenje prema patentnom zahtjevu 14, za sustavnu primjenu odabranu od enteralne primjene i parenteralne primjene.
24. Farmaceutski sastav za korištenje prema patentnom zahtjevu 14, za smanjenje intenziteta ili sprječavanje pogoršanja kožne nuspojave.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538675P | 2017-07-29 | 2017-07-29 | |
| EP18841422.1A EP3661515B1 (en) | 2017-07-29 | 2018-07-26 | Novel braf inhibitors and use thereof for treatment of cutaneous reactions |
| PCT/IL2018/050836 WO2019026065A2 (en) | 2017-07-29 | 2018-07-26 | NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220609T1 true HRP20220609T1 (hr) | 2022-06-24 |
Family
ID=65233550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220609TT HRP20220609T1 (hr) | 2017-07-29 | 2018-07-26 | Novi braf inhibitori i njihovo korištenje za tretiranje kožnih reakcija |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10927112B2 (hr) |
| EP (1) | EP3661515B1 (hr) |
| JP (1) | JP6912667B2 (hr) |
| KR (1) | KR102328351B1 (hr) |
| CN (1) | CN111132680B (hr) |
| AU (1) | AU2018311538B2 (hr) |
| BR (1) | BR112020001935A2 (hr) |
| CA (1) | CA3070542C (hr) |
| DK (1) | DK3661515T3 (hr) |
| ES (1) | ES2908602T3 (hr) |
| HR (1) | HRP20220609T1 (hr) |
| IL (1) | IL272312B (hr) |
| SI (1) | SI3661515T1 (hr) |
| WO (1) | WO2019026065A2 (hr) |
| ZA (1) | ZA202000354B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3072200A1 (en) * | 2017-08-08 | 2019-02-14 | Memorial Sloan Kettering Cancer Center | Use of braf inhibitors for treating cutaneous reactions caused by treatment with a mek inhibitor |
| HUE063091T2 (hu) | 2019-02-12 | 2024-01-28 | Lutris Pharma Ltd | Topikális BRaf inhibitor készítmények alkalmazása besugárzási dermatitis kezelésére |
| CN116669739A (zh) * | 2020-12-24 | 2023-08-29 | 鲁特里斯制药有限公司 | 用于治疗egfr下游效应物诱导的反应的局部braf抑制剂组合物 |
| WO2023275620A2 (en) * | 2021-07-02 | 2023-01-05 | Lutris Pharma Ltd. | Use of isoquinoline-1,5-diamines for wound healing |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753612A (en) | 1992-10-27 | 1998-05-19 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists |
| US7989461B2 (en) * | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| WO2008153947A2 (en) * | 2007-06-07 | 2008-12-18 | Amgen Inc. | Heterocyclic compounds as raf kinase modulators |
| TWI611053B (zh) * | 2012-02-27 | 2018-01-11 | 曾宇鳳 | 為先導藥物最適化之以結構為基礎的片段遷越及合成可行性之改良 |
| KR20140011780A (ko) | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체 |
| BR112015028845A2 (pt) * | 2013-05-30 | 2017-07-25 | Plexxikon Inc | compostos para a modulação da quinase e indicações da mesma |
| CN106535900A (zh) * | 2014-05-06 | 2017-03-22 | 加利福尼亚大学董事会 | 使用braf抑制剂的伤口愈合 |
| WO2017154001A1 (en) * | 2016-03-10 | 2017-09-14 | Lutris Pharma Ltd. | Use of braf inhibitors for treating cutaneous reactions |
-
2018
- 2018-07-26 WO PCT/IL2018/050836 patent/WO2019026065A2/en unknown
- 2018-07-26 SI SI201830670T patent/SI3661515T1/sl unknown
- 2018-07-26 HR HRP20220609TT patent/HRP20220609T1/hr unknown
- 2018-07-26 BR BR112020001935-6A patent/BR112020001935A2/pt unknown
- 2018-07-26 CA CA3070542A patent/CA3070542C/en active Active
- 2018-07-26 KR KR1020207005707A patent/KR102328351B1/ko active IP Right Grant
- 2018-07-26 EP EP18841422.1A patent/EP3661515B1/en active Active
- 2018-07-26 JP JP2020526718A patent/JP6912667B2/ja active Active
- 2018-07-26 CN CN201880060593.7A patent/CN111132680B/zh active Active
- 2018-07-26 AU AU2018311538A patent/AU2018311538B2/en active Active
- 2018-07-26 DK DK18841422.1T patent/DK3661515T3/da active
- 2018-07-26 ES ES18841422T patent/ES2908602T3/es active Active
-
2019
- 2019-06-13 US US16/440,601 patent/US10927112B2/en active Active
-
2020
- 2020-01-17 ZA ZA2020/00354A patent/ZA202000354B/en unknown
- 2020-01-28 IL IL272312A patent/IL272312B/en active IP Right Grant
- 2020-11-20 US US17/100,181 patent/US11339163B2/en active Active
-
2022
- 2022-05-17 US US17/746,446 patent/US20220274988A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10927112B2 (en) | 2021-02-23 |
| CN111132680B (zh) | 2022-02-08 |
| EP3661515A2 (en) | 2020-06-10 |
| JP6912667B2 (ja) | 2021-08-04 |
| RU2020108782A3 (hr) | 2021-09-02 |
| US20210070757A1 (en) | 2021-03-11 |
| IL272312A (en) | 2020-03-31 |
| AU2018311538A1 (en) | 2020-02-13 |
| ZA202000354B (en) | 2024-01-31 |
| US20220274988A1 (en) | 2022-09-01 |
| BR112020001935A2 (pt) | 2020-07-28 |
| ES2908602T3 (es) | 2022-05-03 |
| KR102328351B1 (ko) | 2021-11-19 |
| DK3661515T3 (da) | 2022-04-19 |
| US11339163B2 (en) | 2022-05-24 |
| EP3661515B1 (en) | 2022-02-23 |
| IL272312B (en) | 2021-06-30 |
| EP3661515A4 (en) | 2021-01-06 |
| KR20200035990A (ko) | 2020-04-06 |
| JP2020528933A (ja) | 2020-10-01 |
| WO2019026065A3 (en) | 2019-08-01 |
| US20190389862A1 (en) | 2019-12-26 |
| SI3661515T1 (sl) | 2022-06-30 |
| WO2019026065A2 (en) | 2019-02-07 |
| AU2018311538B2 (en) | 2021-03-25 |
| CA3070542C (en) | 2021-05-18 |
| CA3070542A1 (en) | 2019-02-07 |
| RU2020108782A (ru) | 2021-09-02 |
| CN111132680A (zh) | 2020-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220609T1 (hr) | Novi braf inhibitori i njihovo korištenje za tretiranje kožnih reakcija | |
| JP2022104987A (ja) | ｍＴＯＲ阻害剤の無水組成物およびその使用方法 | |
| Galimont-Collen et al. | Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors | |
| ES2695931T3 (es) | Composiciones y métodos para estimular el crecimiento del pelo | |
| ES2260834T3 (es) | Uso de retinoides a altas dosis para el tratamiento de piel fotodañada. | |
| RU2018135483A (ru) | Использование ингибиторов braf для лечения кожных реакций | |
| JP2011116787A5 (hr) | ||
| JP2020528933A5 (hr) | ||
| JP2013515002A5 (hr) | ||
| US20190167527A1 (en) | Topical antimicrobial compositions and methods of formulating the same | |
| US11173163B2 (en) | Topical antimicrobial compositions and methods of formulating the same | |
| KR20210108414A (ko) | Egfr 억제제를 포함하는 조성물에 의한 피부 장애 치료 | |
| CA2763299C (en) | Method for treating or ameliorating mucocutaneous or ocular toxicities | |
| US12029812B2 (en) | Compositions and methods for treating an infection | |
| WO2012061630A2 (en) | Composition and method for treating skin conditions | |
| JP2021530463A (ja) | ｍＴＯＲ阻害剤の無水組成物および使用方法 | |
| US20200352953A1 (en) | Compositions and methods for treating an infection | |
| US10231908B2 (en) | Method of reducing hair loss associated with chemotherapy | |
| US9402823B2 (en) | Ingenols for treating seborrheic keratosis | |
| JP2012116855A (ja) | 女性型脱毛症等の毛髪成長障害の治療方法とそのために有用な組成物 | |
| US9682033B2 (en) | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound | |
| JP2004131495A (ja) | 非ステロイド系抗炎症剤の局所送達用医薬組成物 | |
| WO2006057375A1 (ja) | 外用製剤 | |
| Gori et al. | Paradoxical effect of infliximab in a patient with hidradenitis suppurativa. | |
| JP6659735B2 (ja) | 日光角化症の治療における水酸化カリウムの使用 |